September 21, 2020 – A KGK Science clinical trial to investigate the efficacy of a natural health product to ease the symptoms of COVID-19 has launched in major cities across Ontario. The Health Canada approved phase 2 clinical trial sponsored by Hofseth Biocare will examine a natural salmon oil-based supplement, CARDIO soft gels, in combination with the clinical management set by the Government of Canada (best standard of care (BSC)) as a therapeutic treatment for former smokers and/or steroid-resistant asthmatics identified with COVID-19.
In the first arm of the trial, patients who are currently self-isolating with COVID-19 will participate in the 28-day study via a virtual platform, allowing KGK to interact one-on-one with each participant from the comfort and safety of their homes while adhering to public health guidelines. In this randomized, open-label, parallel clinical trial, participants will take CARDIO with current BSC or BSC alone and will be provided with all the equipment and resources needed to complete the study assessments virtually. Some of the planned study outcomes include improvements in daily oxygenation requirements, alleviation of COVID-19 related symptoms, and time to clinical recovery. Clinical status will be assessed by a World Health Organization clinical improvement scale.
KGK is actively recruiting participants in the Greater Toronto Area (GTA), Ottawa, Windsor-Essex County, Waterloo, Hamilton, Niagara, Middlesex-London, Guelph, and Simcoe regions to take part in the natural health research study.
The second arm of the study will be conducted in Brazil and Mexico in patients hospitalized for COVID-19. The in-hospital arm is scheduled to begin by late November, pending regional regulatory approvals.
For more information on this clinical trial please contact Lauren Redman, Director of Marketing for KGK Science or visit: https://www.kgkscience.com/research-studies/virtual-trial-examining-cardio-soft-gels-for-covid-19-symptoms/
Contact: Lauren Redman, Director of Marketing | (519) 438-9374 x 254 | firstname.lastname@example.org
This content was originally published here.